170930-04-8

Basic information

• Product Name: tert-butyl 4-(3-methoxy-4-(2-methoxy-2-oxoethyl)phenoxy)piperidine-1-carboxylate
• Synonyms: tert-butyl 4-(3-methoxy-4-(2-methoxy-2-oxoethyl)phenoxy)piperidine-1-carboxylate
• CAS NO: 170930-04-8
• Molecular Weight: 379.453
• Mol File: 170930-04-8.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl 4-(3-methoxy-4-(2-methoxy-2-oxoethyl)phenoxy)piperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 4-(3-methoxy-4-(2-methoxy-2-oxoethyl)phenoxy)piperidine-1-carboxylate(170930-04-8)
• EPA Substance Registry System: tert-butyl 4-(3-methoxy-4-(2-methoxy-2-oxoethyl)phenoxy)piperidine-1-carboxylate(170930-04-8)

Safety Data

• Hazardous Substances Data: 170930-04-8(Hazardous Substances Data)

Upstream product

• 149-73-5 trimethyl orthoformate 
• 89-84-9 2',4'-dihydroxy-4-acetophenone 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 220996-36-1 tert-butyl 4-(4-acetyl-3-hydroxyphenoxy)piperidine-1-carboxylate 
• 36851-80-6 nitrosomethylurea 
• 162045-85-4 2-methoxy-4-(1-Boc-4-piperidyloxy)benzoyl chloride 

Downstream Products

• 162045-86-5 4-(N-tert-butyloxycarbonyl-4-piperidinyloxy)-2-methoxyphenylacetic acid 
• 162045-87-6 4-(3-methoxy-4-{2-oxo-2-[4-(2-oxo-4H-benzo[d][1,3]oxazin-1-yl)-piperidin-1-yl]-ethyl}-phenoxy)-piperidine-1-carboxylic acid tert-butyl ester 
• 196794-09-9 1-(1-{[2-methoxy-4-(piperidin-4-yloxy)-phenyl]-acetyl}-piperidin-4-yl)-1,4-dihydro-benzo[d][1,3]oxazin-2-one 

Relevant articles and documents

Nonpeptide oxytocin antagonists: Analogs of L-371,257 with improved potency

Structure-activity studies on the oxytocin antagonist 1 (L-371,257; K(i) = 9.3 nM) have led to the identification of a related series of compounds containing an ortho-trifluoroethoxyphenylacetyl core which are orally bioavailable and have significantly improved potency in vitro and in vivo, e.g., compound 8 (L-374,943; K(i) = 1.4 nM).

Tocolytic oxytocin receptor antagonists

Compounds of the formula X--Y--R, or the pharmaceutically acceptable salts and esters thereof, wherein X is STR1 Y is --SO2 --, --(CH2)p -- or --CO--(CH2)p --; R is unsubstituted or substituted phenyl where said substitutents are one or more of R5, R6 or R7 ; R1 is hydrogen, cyano, phenyl,--CONHR2, --CONR2 R2, --(CH2)m --OR2, --(CH2)p --S(O)r --R2, --(CH2)m --CO2 R2, --(CH2)m --N3, --(CH2)m --NH2 or --(CH2)m --NR2 R2 ; R2 is hydrogen, C3-8 cycloalkyl or C1-5 alkyl; R5 and R6 are each independently selected from hydrogen, C1-5 alkoxy, halogen or --(CH2)n --N(R2)--C(O)--R18 ; R7 is hydrogen or STR2 R11 is selected from hydrogen, C1-5 alkylcarbonyl, STR3 or substituted C1-5 alkyl wherein said alkyl substituent is unsubstituted, mono-, di- or tri-substituted pyridyl wherein said substitutents on said pyridyl are independently selected from halogen, C1-5 alkyl or C1-5 alkoxyl; R13 is unsubstituted or substituted C1-10 alkyl wherein the substituent is selected from --N(R2)2, --NHR2 or imidazolyl; R14 and R15 are each independently selected from C1-5 alkyl, C1-5 alkoxy or halogen; R16 is hydrogen or oxo; R18 is C1-5 alkoxyl, unsubstituted or substituted C1-5 alkyl where said substituent is Het, unsubstituted or substituted C2-5 alkenyl where said subsituent is Het or Het; Het is benzimidazolyl, carboxymethyl-substituted benzimidazolyl or indolyl; m is an integer of from 1 to 5; p is an integer of from 1 to 3; and r is an integer of from 0 to 2. Such compounds as useful as oxytocin and vasopressin receptor antagonists.